Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Amy Flynt"'
1
RF28 | PSUN198 The Dramatic Fat Mass Loss Caused by Bimagrumab is Similar in Diabetic and Non-diabetic Patients
Autor: Lloyd Klickstein, Amy Flynt, Dawn Edgerton, Kiran Dole, Kevin Nguyen
Publikováno v: Journal of the Endocrine Society. 6:A37-A38
Bimagrumab is a fully human, ligand-blocking antibody to activin receptors type IIA and type IIB that in obese diabetic patients has been shown to improve body composition dramatically. After 48 weeks of treatment (N=75, allocated 1: 1, bimagrumab in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::159c89edd97a538f6dbff24537fd2fb9
https://doi.org/10.1210/jendso/bvac150.077
Zobrazit plný text záznamu
2
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections
Autor: Mark G. Martens, Bassem Maximos, Thorsten Degenhardt, Karen Person, Stacey Curelop, Mahmoud Ghannoum, Amy Flynt, Stephen R. Brand
Publikováno v: American Journal of Obstetrics and Gynecology. 227:880.e1-880.e11
Recurrent vulvovaginal candidiasis affects nearly 138 million women globally each year. In the United States, fluconazole is considered the standard of care for acute vulvovaginal candidiasis, but until recently there was no US Food and Drug Administ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ace389f8ba574e1944a46db51970218
https://doi.org/10.1016/j.ajog.2022.07.023
Zobrazit plný text záznamu
3
Intravenous Ibuprofen Reduces Opioid Consumption During the Initial 48 Hours After Injury in Orthopedic Trauma Patients
Autor: Ines Macias-Perez, Vivian Lerner, Russell Weisz, Ivan Puente, Maggie Crawford, Alexander A Fokin, Leo Pavliv, Amy Flynt
Publikováno v: Journal of Orthopaedic Trauma
Supplemental Digital Content is Available in the Text.
Objectives: To evaluate the efficacy of intravenous (IV) ibuprofen (Caldolor) administration in the management of acute pain in orthopedic trauma patients and to minimize opioid use. Design:
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f32baee567d147a448783d4ba0605415
https://pubmed.ncbi.nlm.nih.gov/31929374
Zobrazit plný text záznamu
4
Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy
Autor: Michelle Eli, Joanne Sloan-Lancaster, Mark A. Deeg, Eyas Raddad, James Tumlin, Amy Flynt
Publikováno v: Clinical Pharmacology in Drug Development. 7:759-772
Two phase 1 studies (TGAA and TGAB) evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of LY3016859 (LY), a monoclonal antibody that binds epiregulin and transforming growth factor α (TGF-α), administered intravenously or subcut
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2884d33a5fd60a1a8262fd27f9ef34be
https://doi.org/10.1002/cpdd.436
Zobrazit plný text záznamu
5
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer
Autor: Michael McCleod, David R. Spigel, Oday Hamid, R. Waide Weaver, Ravi Salgia, John Polzer, John R. Stille, Stephanie Roberson, Amy Flynt
Publikováno v: Lung Cancer. 105:7-13
Objectives This multicenter, open-label, randomized phase II study evaluated the efficacy and safety of LY2510924 (LY) added to first‐line standard of care (SOC) chemotherapy for extensive-disease small cell lung cancer (ED-SCLC) and explored the p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c6b5bc6e6936b3ae1d6b443c1b054c
https://doi.org/10.1016/j.lungcan.2016.12.020
Zobrazit plný text záznamu
7
A Clinical Trial of Intravenous Peramivir Compared with Oral Oseltamivir for the Treatment of Seasonal Influenza in Hospitalized Adults
Autor: David S.C. Hui, Amy Flynt, Michael G. Ison, W. James Alexander, Kate Clezy, Thomas J. Simon, Philip J. Collis, Brian J. O'Neil
Publikováno v: Antiviral Therapy. 18:651-661
Background Seasonal interpandemic influenza causes >200,000 annual hospitalizations in the United States. Optimal antiviral treatment in hospitalized patients is not established. Methods During three interpandemic influenza seasons, 137 patients hosp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da56ee4ec1bc0b41eca5103bd2168e97
https://doi.org/10.3851/imp2442
Zobrazit plný text záznamu
8
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
Autor: James A. Reeves, Amy Flynt, Oday Hamid, Stephanie Roberson, Edward J. Crane, John D. Hainsworth, John Polzer, Edward Arrowsmith, John R. Stille, Joseph R. Mace
Publikováno v: Targeted oncology. 11(5)
The chemokine (C-X-C Motif) receptor 4 (CXCR4) and its ligand, stromal-cell derived factor-1 (SDF-1), are frequently overexpressed in a variety of solid tumors, and are believed to play important roles in the regulation of organ-specific metastasis,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fcbb96354eb241f5becd255dbee45ac
https://pubmed.ncbi.nlm.nih.gov/27154357
Zobrazit plný text záznamu
9
Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza
Autor: Priyesh Mehta, James Peterson, Katie Julien, Rajasekaran Annamalai, John A. Vanchiere, Sylvia Dobo, Eniko Nagy, Amy Flynt, Deborah Kargl, Stephanie Plunkett, Flor M. Munoz, Amanda Mathis, Shane Christensen, Phil Collis, Stephen Coleman, William P. Sheridan, Marcy Goisse
Publikováno v: Open Forum Infectious Diseases
Background Peramivir (PVR) is a potent neuraminidase inhibitor with in vitro activity against all influenza virus subtypes. Previous studies demonstrated the efficacy and safety of PVR as a single dose intravenous (IV) treatment for acute uncomplicat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f00bbc7a710f9f6ff475a2041983a4c
http://europepmc.org/articles/PMC5630974
Zobrazit plný text záznamu
10
LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase
Autor: Eyas Raddad, Joanne Sloan-Lancaster, James Voelker, Amy Flynt, Y. Jin, Jeffrey W. Miller
Publikováno v: Journal of the Renin-Angiotensin-Aldosterone System, Vol 18 (2017)
Journal of the Renin-Angiotensin-Aldosterone System: JRAAS
Introduction:LY3045697 is a potent and selective aldosterone synthase (CYP11B2) inhibitor that was developed as a safer alternative to mineralocorticoid receptor antagonists. Effects of LY3045697 on aldosterone and cortisol synthesis, as well as pota
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfa00933f3a7c06aff444f7c4ab18a62
https://doi.org/10.1177/1470320317717883
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje